Journal
CIRCULATION
Volume 136, Issue 16, Pages E232-E268Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIR.0000000000000525
Keywords
AHA Scientific Statements; delivery of health care; disease management; shock, cardiogenic
Funding
- St. Jude Medical
- Abbott Vascular
- AstraZeneca
- Abiomed
- St. Jude
- Cardiac Assist
- Maquet
- Daiichi Sankyo
- Gilead Sciences
- Janssen Pharmaceuticals
- AHA
- Novartis
- Merck
- European Union
- Medtronic Foundation
- Pfizer
- Bristol Myers Squibb
Ask authors/readers for more resources
Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite improving survival in recent years, patient morbidity and mortality remain high, and there are few evidence-based therapeutic interventions known to clearly improve patient outcomes. This scientific statement on cardiogenic shock summarizes the epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, surgical, mechanical circulatory support, and palliative care practices; advocates for the development of regionalized systems of care; and outlines future research priorities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available